Loading...
Loading...
TAK| Name | Value |
|---|---|
| Revenues | 1,043.1B |
| Cost of Revenue | 343.6B |
| Gross Profit | 699.5B |
| Operating Expense | 748.9B |
| Operating I/L | -49.3B |
| Other Income/Expense | -46.6B |
| Interest Income | 9.4B |
| Pretax | -96.0B |
| Income Tax Expense | -48.0B |
| Net Income/Loss | -48.0B |
Takeda Pharmaceutical Company Limited is a global pharmaceutical company that focuses on research, development, manufacturing, marketing, and out-licensing of pharmaceutical products. The company's product portfolio includes pharmaceuticals in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. It offers a range of branded pharmaceutical products under various well-known brands such as Entyvio, Gattex/Revestive, Takecab, and others. Takeda also engages in collaborations, in-licensing agreements, and strategic alliances with various biotech and pharmaceutical companies to drive innovation and expand its product offerings.
